Association of Polymorphisms in Plasminogen Activator Inhibitor-1 (PAI-1), Tissue Plasminogen Activator (tPA), and Renin (REN) with Recurrent Pregnancy Loss in Korean Women

被引:5
|
作者
Cho, Hee Young [1 ]
Park, Han Sung [2 ]
Ahn, Eun Hee [3 ]
Ko, Eun Ju [2 ]
Park, Hyeon Woo [2 ]
Kim, Young Ran [3 ]
Kim, Ji Hyang [3 ]
Lee, Woo Sik [4 ]
Kim, Nam Keun [2 ]
机构
[1] CHA Univ, Dept Obstet & Gynecol, CHA Gangnam Med Ctr, Seoul 06135, South Korea
[2] CHA Univ, Dept Biomed Sci, Coll Life Sci, Seongnam 13488, South Korea
[3] CHA Univ, Dept Obstet & Gynecol, CHA Bundang Med Ctr, Seongnam 13496, South Korea
[4] CHA Univ, Fertil Ctr, CHA Gangnam Med Ctr, Seoul 06135, South Korea
来源
JOURNAL OF PERSONALIZED MEDICINE | 2021年 / 11卷 / 12期
基金
新加坡国家研究基金会;
关键词
plasminogen activator inhibitor-1; tissue plasminogen activator; renin; polymorphism; recurrent pregnancy loss; CORONARY-ARTERY-DISEASE; GENE POLYMORPHISM; T-PA; ANGIOTENSIN; RISK; INFLAMMATION; VARIANTS; RELEASE; SYSTEM; TYPE-1;
D O I
10.3390/jpm11121378
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Recurrent pregnancy loss (RPL) is defined as two or more consecutive pregnancy losses prior to 20 weeks of gestational age. Various factors, including immune dysfunction, endocrine disorders, coagulation abnormality, and genetic disorders influence RPL. In particular, plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (tPA), and renin (REN) have important roles in the thrombotic and thrombolytic systems, and abnormal expression of these genes have a reported negative correlation with pregnancy maintenance. Moreover, some polymorphisms of the three genes are related to expression levels and thrombotic disorder. Therefore, we investigated whether polymorphisms of PAI-1, tPA, and REN are linked to RPL. Genotyping of the six polymorphisms (PAI-1 rs11178, rs1050955, tPA rs4646972, rs2020918, REN rs1464816, and rs5707) was performed using polymerase chain reaction (PCR)-restriction fragment length polymorphism and associations of the polymorphisms with RPL were evaluated by statistical analysis. The polymorphism PAI-1 rs1050955 GA+AA was associated with decreased RPL risk (AOR, 0.528; 95% CI 0.356-0.781; p = 0.001) as was the REN 10795 rs5707 GG genotype (AOR, 0.487; 95% CI 0.301-0.787; p = 0.003). In contrast, the tPA rs4646972 II genotype correlated with increased RPL risk (AOR, 1.606; 95% CI, 1.047-2.463; p = 0.030). This study provides evidence that tPA Alu rs4646972 may contribute to the risk of idiopathic RPL, but PAI-1 12068 rs1050955 and REN 10795 rs5707 are associated with a decreased risk of RPL. Therefore, these alleles may be useful as biomarkers to evaluate the risk of RPL.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] BEHAVIOR OF TISSUE PLASMINOGEN-ACTIVATOR, PLASMINOGEN-ACTIVATOR INHIBITOR-1 AND THEIR COMPLEX IN VARIOUS DISEASE STATES
    NIWANO, H
    TAKAHASHI, H
    TATEWAKI, W
    WADA, K
    SEKI, Y
    SHIBATA, A
    BLOOD COAGULATION & FIBRINOLYSIS, 1992, 3 (04) : 389 - 393
  • [42] Protection by alpha 2-macroglobulin of tissue plasminogen activator against inhibition by plasminogen activator inhibitor-1
    Ieko, M
    Sawada, K
    Yasukouchi, T
    Sakurama, S
    Tohma, Y
    Shiroshita, K
    Kurosawa, S
    Ohmoto, A
    Kohno, M
    Satoh, M
    Koike, T
    BRITISH JOURNAL OF HAEMATOLOGY, 1997, 97 (01) : 214 - 218
  • [43] Plasminogen activator inhibitor-1 removal using dextran sulphate columns. Evidence of PAI-1 homeostasis
    Vincent M. G. Maher
    Yuri Kitano
    Clare Neuwirth
    Graham J. Davies
    Attilio Maseri
    Gilbert R. Thompson
    Felicita Andreotti
    Journal of Thrombosis and Thrombolysis, 2009, 28 : 166 - 172
  • [44] DISTURBANCES IN THE TISSUE PLASMINOGEN-ACTIVATOR PLASMINOGEN-ACTIVATOR INHIBITOR (TPA/PAI) SYSTEM IN SYSTEMIC LUPUS-ERYTHEMATOSUS
    RUIZARGUELLES, GJ
    RUIZARGUELLES, A
    LOBATOMENDIZABAL, E
    DIAZGOMEZ, F
    PACHECOPANTOJA, E
    DRENKARD, C
    ALARCONSEGOVIA, D
    AMERICAN JOURNAL OF HEMATOLOGY, 1991, 37 (01) : 9 - 13
  • [45] Plasminogen activator inhibitor-1 (PAI-1) antigen plasma levels in subjects attending a metabolic ward: Relation to polymorphisms of PAI-1 and angiotensin converting enzyme (ACE) genes
    Margaglione, M
    Grandone, E
    Vecchione, G
    Cappucci, G
    Giuliani, N
    Colaizzo, D
    Celentano, E
    Panico, S
    DiMinno, G
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (10) : 2082 - 2087
  • [46] Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors
    Lampelj, Maja
    Arko, Darja
    Cas-Sikosek, Nina
    Kavalar, Rajko
    Ravnik, Maja
    Jezersek-Novakovic, Barbara
    Dobnik, Sarah
    Dovnik, Nina Fokter
    Takac, Iztok
    RADIOLOGY AND ONCOLOGY, 2015, 49 (04) : 357 - 364
  • [47] Impacts of dynamic mechanical stretch on the expression of plasminogen activator inhibitor-1 (PAI-1) in human A549 cells
    Guo, Yongqing
    Zhang, Weiwei
    Zheng, Lina
    Guo, Weixing
    Zhang, Huaping
    Li, Xiaona
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2016, 9 (06): : 5871 - 5881
  • [48] Structural Basis for Recognition of Urokinase-type Plasminogen Activator by Plasminogen Activator Inhibitor-1
    Lin, Zhonghui
    Jiang, Longguang
    Yuan, Cai
    Jensen, Jan K.
    Zhang, Xu
    Luo, Zhipu
    Furie, Barbara C.
    Furie, Bruce
    Andreasen, Peter A.
    Huang, Mingdong
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (09) : 7027 - 7032
  • [49] Association between Plasma Levels of Plasminogen Activator Inhibitor-1 and Colorectal Neoplasms
    Kim, Eun Ran
    Yang, Mun Hee
    Lim, Yeun Jung
    Lee, Jin Hee
    Chang, Dong Kyung
    Kim, Young-Ho
    Son, Hee Jung
    Kim, Jae J.
    Rhee, Jong Chul
    Kim, Jin Yong
    GUT AND LIVER, 2013, 7 (05) : 519 - 523
  • [50] INCREASED LEVELS OF TISSUE PLASMINOGEN-ACTIVATOR WITH A LOW PLASMINOGEN-ACTIVATOR INHIBITOR-1 IN A PATIENT WITH POSTOPERATIVE BLEEDING
    STANKIEWICZ, AJ
    CROWLEY, JP
    STEINER, M
    AMERICAN JOURNAL OF HEMATOLOGY, 1991, 38 (03) : 226 - 229